Helix BioPharma Corp. (TSX:HBP)
Canada · Delayed Price · Currency is CAD | Market Cap | 140.54M +186.7% |
| Revenue (ttm) | n/a |
| Net Income | -4.88M |
| EPS | -0.08 |
| Shares Out | 76.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 966 |
| Average Volume | 2,270 |
| Open | 1.840 |
| Previous Close | 1.850 |
| Day's Range | 1.780 - 1.840 |
| 52-Week Range | 0.650 - 5.400 |
| Beta | -0.35 |
| RSI | 38.34 |
| Earnings Date | Mar 13, 2026 |
About Helix BioPharma
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is ... [Read more]
Financial Performance
Financial StatementsNews
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
(Toronto, Ontario; February 5, 2026) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping...
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
Toronto, Ontario – TheNewswire - 30 January, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC: “HBPCF” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a nea...
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
Toronto, Ontario – TheNewswire - 15 December, 2025 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping...
Helix Biopharma GAAP EPS of -$0.09
Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
Toronto, Ontario – TheNewswire - 29 October 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a near fu...
Helix BioPharma Responds to Market Activity
Toronto, Ontario – TheNewswire - 6 October 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a near fut...
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Toronto, Ontario – TheNewswire - 9 September 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a near f...
Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM
Toronto, Ontario – TheNewswire - 5 September 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a near f...
Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting
Toronto, Ontario (22 August 2025) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a near fut...
Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC
Toronto, Ontario – TheNewswire - 13 August 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a nea...
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025
(Toronto, Ontario) – Helix BioPharma Corp. - TheNewswire - (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a near future w...
Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones
2 June 2025 – TheNewswire - (Toronto, Ontario) – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a n...
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group
May 20 , 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a n...
Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.
May 14, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ne...
Helix BioPharma Corp. Appoints New COO and Communications Director to Accelerate Growth and Deliver on its Mission Against Hard-to-Treat Cancers
Toronto, Ontario – TheNewswire – April 24, 2025 - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ...
Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan
April 10, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ...
Urgent Solutions to Fight Cancer: How Helix BioPharma is Tackling the Toughest Challenges
Helix BioPharma is a clinical-stage biopharmaceutical company aiming to turn scientific breakthroughs into real-world solutions for some of the most difficult-to-treat cancers.
Helix BioPharma Corp. Announces Engagement of Independent Trading Group to Provide Market-Making Services
April 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a n...
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
March 26, 2025 - (Toronto, Ontario) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a nea...
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025
March 18, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ...
Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain
March 11, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a ...
Helix Biopharma Corp. Expands Leadership Team with World-Class Oncology and Scientific Experts
March 6, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology company shaping a near...
Helix BioPharma Corp. receives approval for the Extension of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing
March 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“ Helix ” or the “ Company ”), a clinical-stage oncology company shaping a ne...
Helix BioPharma Corp. Extends Date of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing
February 24, 2025 - (Toronto, Ontario) – TheNewswire – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a ...
Helix Biopharma appoints James Murphy as CFO
Helix BioPharma appoints James Murphy as Chief Financial Officer, previously a consultant with Danforth Advisors.